These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4433355)

  • 1. Hemarthrosis as the presenting manifestation of myeloproliferative disease.
    Harris BK; Ross HA
    Arthritis Rheum; 1974; 17(6):969-70. PubMed ID: 4433355
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemarthrosis as the presenting manifestation of myeloproliferative disease.
    Jackson WH; Harris BK; Ross HA
    Ariz Med; 1975 Apr; 32(4):281-3. PubMed ID: 1119948
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet function after busulphan in chronic myeloproliferative disorders.
    Barbui T; Bassan R; Viero P; Cortelazzo S; Dini E
    Haematologica; 1983; 68(4):469-77. PubMed ID: 6414897
    [No Abstract]   [Full Text] [Related]  

  • 4. Alteration of platelets and virus-like particles by busulfan in myeloproliferative disorders.
    Fuscaldo AA; Erlick BJ; Brodsky I; Fuscaldo KE
    Leuk Res; 1980; 4(1):105-17. PubMed ID: 6157962
    [No Abstract]   [Full Text] [Related]  

  • 5. An unusual case of myeloproliferative disease which started with erythroderma: chronic (incomplete) panmyelosis.
    Gorini M; Ghizzi A; Bobbio Pallavicini E; Perugini S
    Haematologica; 1979 Dec; 64(6):804-11. PubMed ID: 161880
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of myeloproliferative diseases].
    Burkhardt R
    Munch Med Wochenschr; 1973 May; 115(19):878-91. PubMed ID: 4800219
    [No Abstract]   [Full Text] [Related]  

  • 7. Some uses of the continuous flow blood separator in the myeloproliferative syndrome.
    Bell R; Sullivan JR; Hurley TH; D'Apice AJ; Kincaid-Smith P
    Aust N Z J Med; 1978 Aug; 8(4):433-5. PubMed ID: 282861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.
    Begna K; Abdelatif A; Schwager S; Hanson C; Pardanani A; Tefferi A
    Blood Cancer J; 2016 May; 6(5):e427. PubMed ID: 27232929
    [No Abstract]   [Full Text] [Related]  

  • 9. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
    Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
    Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case 1-2013: fatal manifestation of myeloproliferative disease.
    Sevcíková H; Pelouch R; Matejková A; Dulícek P
    Acta Medica (Hradec Kralove); 2013; 56(1):33-5. PubMed ID: 23909053
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease.
    Tabarroki A; Visconte V; Rogers HJ; Sekeres MA; Samaras C; Lichtin A; Duong HK; Englehaupt R; Cinalli T; Dodd K; Desamito J; Rouphail B; Altman JK; Stein BL; Tiu RV
    Leuk Lymphoma; 2014 Jan; 55(1):213-6. PubMed ID: 23607256
    [No Abstract]   [Full Text] [Related]  

  • 12. Myeloproliferative diseases in childhood.
    Nix WL; Fernbach DJ
    Am J Pediatr Hematol Oncol; 1981; 3(4):397-407. PubMed ID: 6174053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients presenting with CNS lesions. Case 3. Sequential myeloproliferative disease and glioblastoma multiforme in a renal transplant recipient.
    Au WY; Hung KN; Loong F; Ma SK
    J Clin Oncol; 2003 Nov; 21(21):4062-3. PubMed ID: 14581430
    [No Abstract]   [Full Text] [Related]  

  • 14. Abnormalities of platelet function in the myeloproliferative disorders.
    Cardamone JM; Edson JR; McArthur JR; Jacob HS
    JAMA; 1972 Jul; 221(3):270-3. PubMed ID: 4504007
    [No Abstract]   [Full Text] [Related]  

  • 15. [The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease].
    Jantunen E; Penttilä K; Kuittinen T; Nousiainen T
    Duodecim; 2006; 122(4):453-7. PubMed ID: 16623100
    [No Abstract]   [Full Text] [Related]  

  • 16. The myeloproliferative syndromes.
    Linman JW
    Hosp Pract (Off Ed); 1986 Apr; 21(4):116A-116CC. PubMed ID: 3082901
    [No Abstract]   [Full Text] [Related]  

  • 17. [Thrombosis in various diseases: myeloproliferative disorders].
    Niikura H
    Nihon Rinsho; 1986 May; 44(5):1144-52. PubMed ID: 2943916
    [No Abstract]   [Full Text] [Related]  

  • 18. Platelet defects in the myeloproliferative disorders.
    Inceman S; Tangün Y
    Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of myeloproliferative diseases.
    Sellei C
    Ther Hung; 1966; 14(4):135-6. PubMed ID: 5228101
    [No Abstract]   [Full Text] [Related]  

  • 20. [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
    Fourgeaud C; El Nemer W; Michon Pasturel U; Bonhomme S; Brignier A; Lazareth I; Priollet P
    J Mal Vasc; 2015 Dec; 40(6):350-8. PubMed ID: 26362408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.